BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 22562985)

  • 21. The effects of glycemic index on prostate cancer progression in a xenograft mouse model.
    Galván GC; Macias E; Sanders S; Ramirez-Torres A; Stock S; You S; Riera CE; Tamukong P; Smith-Warner SA; Genkinger JM; Luthringer DJ; Freeman MR; Freedland SJ
    Prostate Cancer Prostatic Dis; 2024 Jun; 27(2):348-354. PubMed ID: 38082056
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epitope-specific mechanisms of IGF1R inhibition by ganitumab.
    Calzone FJ; Cajulis E; Chung YA; Tsai MM; Mitchell P; Lu J; Chen C; Sun J; Radinsky R; Kendall R; Beltran PJ
    PLoS One; 2013; 8(2):e55135. PubMed ID: 23383308
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of ganitumab (AMG 479), alone and in combination with rapamycin, in Ewing's and osteogenic sarcoma models.
    Beltran PJ; Chung YA; Moody G; Mitchell P; Cajulis E; Vonderfecht S; Kendall R; Radinsky R; Calzone FJ
    J Pharmacol Exp Ther; 2011 Jun; 337(3):644-54. PubMed ID: 21385891
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combination of anti-IGF-1R antibody A12 and ionizing radiation in upper respiratory tract cancers.
    Riesterer O; Yang Q; Raju U; Torres M; Molkentine D; Patel N; Valdecanas D; Milas L; Ang KK
    Int J Radiat Oncol Biol Phys; 2011 Mar; 79(4):1179-87. PubMed ID: 21129859
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-IGF-1R monoclonal antibody inhibits the carcinogenicity activity of acquired trastuzumab-resistant SKOV3.
    Wang W; Zhang Y; Lv M; Feng J; Peng H; Geng J; Lin Z; Zhou T; Li X; Shen B; Ma Y; Qiao C
    J Ovarian Res; 2014 Nov; 7():103. PubMed ID: 25424625
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma.
    Desbois-Mouthon C; Baron A; Blivet-Van Eggelpoël MJ; Fartoux L; Venot C; Bladt F; Housset C; Rosmorduc O
    Clin Cancer Res; 2009 Sep; 15(17):5445-56. PubMed ID: 19706799
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of forced expression of mutated K-RAS gene on gastrointestinal cancer cell lines and the IGF-1R targeting therapy.
    Matsunaga Y; Adachi Y; Sasaki Y; Koide H; Motoya M; Nosho K; Takagi H; Yamamoto H; Sasaki S; Arimura Y; Tokino T; Carbone DP; Imai K; Shinomura Y
    Mol Carcinog; 2017 Feb; 56(2):515-526. PubMed ID: 27312358
    [TBL] [Abstract][Full Text] [Related]  

  • 28. IGF-1R targeting increases the antitumor effects of DNA-damaging agents in SCLC model: an opportunity to increase the efficacy of standard therapy.
    Ferté C; Loriot Y; Clémenson C; Commo F; Gombos A; Bibault JE; Fumagalli I; Hamama S; Auger N; Lahon B; Chargari C; Calderaro J; Soria JC; Deutsch E
    Mol Cancer Ther; 2013 Jul; 12(7):1213-22. PubMed ID: 23640142
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The association of TP53 mutations with the resistance of colorectal carcinoma to the insulin-like growth factor-1 receptor inhibitor picropodophyllin.
    Wang Q; Wei F; Lv G; Li C; Liu T; Hadjipanayis CG; Zhang G; Hao C; Bellail AC
    BMC Cancer; 2013 Nov; 13():521. PubMed ID: 24182354
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of anti-insulin-like growth factor I receptor monoclonal antibody cixutumumab in mesothelioma is highly correlated with insulin growth factor-I receptor sites/cell.
    Kalra N; Zhang J; Yu Y; Ho M; Merino M; Cao L; Hassan R
    Int J Cancer; 2012 Nov; 131(9):2143-52. PubMed ID: 22323052
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Simvastatin inhibits the proliferation of human prostate cancer PC-3 cells via down-regulation of the insulin-like growth factor 1 receptor.
    Sekine Y; Furuya Y; Nishii M; Koike H; Matsui H; Suzuki K
    Biochem Biophys Res Commun; 2008 Jul; 372(2):356-61. PubMed ID: 18489904
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of insulin-like growth factor-I receptor (IGF-IR) signaling and tumor cell growth by a fully human neutralizing anti-IGF-IR antibody.
    Wang Y; Hailey J; Williams D; Wang Y; Lipari P; Malkowski M; Wang X; Xie L; Li G; Saha D; Ling WL; Cannon-Carlson S; Greenberg R; Ramos RA; Shields R; Presta L; Brams P; Bishop WR; Pachter JA
    Mol Cancer Ther; 2005 Aug; 4(8):1214-21. PubMed ID: 16093437
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association of diet-induced hyperinsulinemia with accelerated growth of prostate cancer (LNCaP) xenografts.
    Venkateswaran V; Haddad AQ; Fleshner NE; Fan R; Sugar LM; Nam R; Klotz LH; Pollak M
    J Natl Cancer Inst; 2007 Dec; 99(23):1793-800. PubMed ID: 18042933
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The strength of small: improved targeting of insulin-like growth factor-1 receptor (IGF-1R) with F(ab')₂-R1507 fragments in Ewing sarcomas.
    Fleuren ED; Versleijen-Jonkers YM; Heskamp S; Roeffen MH; Bouwman WH; Molkenboer-Kuenen JD; van Laarhoven HW; Oyen WJ; Boerman OC; van der Graaf WT
    Eur J Cancer; 2013 Sep; 49(13):2851-8. PubMed ID: 23664098
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Id1-induced IGF-II and its autocrine/endocrine promotion of esophageal cancer progression and chemoresistance--implications for IGF-II and IGF-IR-targeted therapy.
    Li B; Tsao SW; Chan KW; Ludwig DL; Novosyadlyy R; Li YY; He QY; Cheung AL
    Clin Cancer Res; 2014 May; 20(10):2651-62. PubMed ID: 24599933
    [TBL] [Abstract][Full Text] [Related]  

  • 36. IGF1R blockade with ganitumab results in systemic effects on the GH-IGF axis in mice.
    Moody G; Beltran PJ; Mitchell P; Cajulis E; Chung YA; Hwang D; Kendall R; Radinsky R; Cohen P; Calzone FJ
    J Endocrinol; 2014 Apr; 221(1):145-55. PubMed ID: 24492468
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antibody targeting of the insulin-like growth factor I receptor enhances the anti-tumor response of multiple myeloma to chemotherapy through inhibition of tumor proliferation and angiogenesis.
    Wu KD; Zhou L; Burtrum D; Ludwig DL; Moore MA
    Cancer Immunol Immunother; 2007 Mar; 56(3):343-57. PubMed ID: 16832681
    [TBL] [Abstract][Full Text] [Related]  

  • 38. R1507, an anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, and EWS/FLI-1 siRNA in Ewing's sarcoma: convergence at the IGF/IGFR/Akt axis.
    Huang HJ; Angelo LS; Rodon J; Sun M; Kuenkele KP; Parsons HA; Trent JC; Kurzrock R
    PLoS One; 2011; 6(10):e26060. PubMed ID: 22022506
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Up-regulation of insulin-like growth factor binding protein-3 by apigenin leads to growth inhibition and apoptosis of 22Rv1 xenograft in athymic nude mice.
    Shukla S; Mishra A; Fu P; MacLennan GT; Resnick MI; Gupta S
    FASEB J; 2005 Dec; 19(14):2042-4. PubMed ID: 16230333
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The level of insulin growth factor-1 receptor expression is directly correlated with the tumor uptake of (111)In-IGF-1(E3R) in vivo and the clonogenic survival of breast cancer cells exposed in vitro to trastuzumab (Herceptin).
    Cornelissen B; McLarty K; Kersemans V; Reilly RM
    Nucl Med Biol; 2008 Aug; 35(6):645-53. PubMed ID: 18678349
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.